Related Experiment Videos
Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes
T Todo1, S D Rabkin, P Sundaresan
1Department of Neurosurgery, Georgetown University Medical Center, Washington, DC 20007, USA. todot@odrge.odr.georgetown.edu
Human Gene Therapy
|December 10, 1999
Summary
Replication-competent herpes simplex virus (HSV) G207 effectively treats brain tumors by causing tumor regression and eliciting a lasting systemic immune response. This viral therapy enhances antitumor immunity, offering protection against tumor recurrence in both the brain and periphery.
Area of Science:
- Oncology
- Immunology
- Virology
Background:
- Malignant brain tumors are challenging to treat, and the role of host immune responses in viral oncolytic therapy within the brain remains unclear.
- Replication-competent, attenuated herpes simplex virus (HSV) vectors are being explored for oncolytic therapy against brain tumors.
Purpose of the Study:
- To evaluate the therapeutic efficacy of the G207 HSV vector in an immunocompetent model of brain tumors.
- To investigate the host immune responses elicited by G207 in treating neuroblastoma.
Main Methods:
- N18 neuroblastoma cells were used as a tumor model in syngeneic A/J mice.
- G207, a conditionally replicating HSV vector, was administered intraneoplastically and subcutaneously.
- Therapeutic efficacy and systemic antitumor immune responses were assessed.
Main Results:
- Intraneoplastic G207 inoculation demonstrated significant oncolytic antitumor effects against brain and subcutaneous N18 tumors.
- G207 therapy induced a systemic antitumor immune response, leading to regression of remote tumors.
- Subcutaneous G207 treatment provided persistent, tumor-specific protection against rechallenge in the brain and periphery.
- Antitumor immunity correlated with elevated, long-lasting cytotoxic T lymphocyte (CTL) activity against N18 cells.
Conclusions:
- Replication-competent HSV oncolytic therapy can be augmented by inducing specific and systemic antitumor immunity.
- This approach shows potential for treating brain tumors by engaging both direct viral oncolysis and immune-mediated mechanisms.
- The findings suggest G207's efficacy extends beyond direct tumor killing to stimulating protective systemic immunity.